MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
The first and only FDA-approved once-daily amoxicillin will be promoted to health care professionals nationwide
“We’re in the process of securing national retail distribution for Moxatag across the food, drug and mass channels, which includes independent and chain retailers,” Thievon continued. “The entire MiddleBrook team is working diligently to ensure the successful launch of Moxatag, and as a result of our efforts to date, I’m extremely pleased to announce that Moxatag’s professional launch will begin on
MiddleBrook plans to hire sales representatives to fill the remaining open positions for its field force over the next several weeks. Interested job applicants can find more information about MiddleBrook’s open positions and apply online at the Careers section of MiddleBrook’s web site, www.middlebrookpharma.com.
MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350
MiddleBrook Pharmaceuticals also announced today that on
About MiddleBrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We are currently developing a portfolio of anti-infective products utilizing our proprietary, once-a-day pulsatile delivery technology called Pulsys. Our near-term corporate strategy is to improve dosing regimens and/or frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag – the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit www.middlebrookpharma.com.
Moxatag (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of Moxatag are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. Moxatag is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about Moxatag, please visit www.middlebrookpharma.com.
This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “potential, ” “estimate, ” “will,” “may,” “predict,” “should, ” “could, ” “would” and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended
SOURCE MiddleBrook Pharmaceuticals, Inc.